CORRECTION article

Front. Immunol., 22 January 2026

Sec. Cancer Immunity and Immunotherapy

Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1789441

Correction: IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities

Article metrics

View details

474

Views

49

Downloads

There was a mistake in Figure 1 as published. In the PDF of the article, the revised version of the Figure was not included. However, it is correct on the webpage. The corrected Figure 1 appears below.

Figure 1

The original version of this article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

cancer-associated fibroblasts, interleukin-6, prostate cancer, therapeutic resistance, tumor microenvironment

Citation

Frontiers Production Office (2026) Correction: IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities. Front. Immunol. 17:1789441. doi: 10.3389/fimmu.2026.1789441

Received

16 January 2026

Accepted

16 January 2026

Published

22 January 2026

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

17 - 2026

Updates

Copyright

*Correspondence: Frontiers Production Office,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics